Nuvectis Pharma Inc.
(NVCT)
undefined
undefined%
At close: undefined
4.70
-0.69%
After-hours Dec 13, 2024, 04:00 PM EST
Company Description
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology.
It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases.
The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Nuvectis Pharma Inc.
| Country | United States |
| IPO Date | Feb 4, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Ron Bentsur M.B.A. |
Contact Details
Address: 1 Bridge Plaza Fort Lee, New Jersey United States | |
| Website | https://www.nuvectis.com |
Stock Details
| Ticker Symbol | NVCT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001875558 |
| CUSIP Number | 67080T108 |
| ISIN Number | US67080T1088 |
| Employer ID | 86-2405608 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ron Bentsur M.B.A. | Co-Founder, Chairman, Chief Executive Officer & President |
| Dr. Enrique Poradosu Ph.D. | Co-Founder, Executive Vice President, Chief Scientific & Business Officer |
| Michael Carson CPA | Vice President of Finance |
| Shay Shemesh | Co-Founder, Executive Vice President, Chief Development & Operations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | 4 | Filing |
| Nov 18, 2024 | 4 | Filing |
| Nov 08, 2024 | 4 | Filing |
| Nov 05, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 05, 2024 | 10-Q | Quarterly Report |
| Nov 05, 2024 | 8-K | Current Report |
| Aug 29, 2024 | 8-K | Current Report |
| Aug 06, 2024 | 10-Q | Quarterly Report |
| Aug 06, 2024 | 8-K | Current Report |
| Jun 13, 2024 | 4 | Filing |